Clinical trials: Vulvovaginal Candidiasis
Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.
- Conditions
- Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
- Trial name
- NCT07109869
- Testing
- Boric acid
- Where
- 26 sites in United States
- Volunteers
- 333 people
- Sponsor
- pH-D Feminine Health LLC
Candidiasis, Vulvovaginal
Vulvovaginal Candidiasis in Canadian Females
Vulvovaginal candidiasis (VVC; colloquially referred to as a 'yeast infection') is a prevalent mucosal infection caused by Candida spp. that affects ~75% of women at least once in their life.
- Trial name
- THRIVE-yeast (NCT04930107)
- Testing
- Fluconazole 150 mg, Boric Acid Supp,Vag
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Vulvovaginal Candidiasis, Bacterial Vaginosis
Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
The overall objective of this clinical pilot study is to determine at a random sampling time, the vaginal microbiome and metabolome of pregnant women, and to see if infection (bacterial vaginosis, vulvovaginal candidiasis…
- Trial name
- RVMM (NCT02150655)
- Testing
- Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules
- Where
- Rwanda
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Vulvovaginal Candidiasis
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of…
- Trial name
- NCT00803738
- Testing
- Terconazole Vaginal Suppository, Terazol Vaginal Suppository
- Volunteers
- 572 people
- Sponsor
- Padagis LLC
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Vulvo-vaginal Candidiasis
Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis
This study aims to evaluate the effect of a specific strain of Saccharomyces cerevisiae on improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis.
- Trial name
- NCT02345096
- Testing
- Saccharomyces cerevisiae
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Lesaffre International
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Candidosis Vaginal
Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers
The study object of this clinical trial is CanProFem-AK, 100 mg suppositories. The Pharmacological group - Antifungal drug for external use.
- Trial name
- NCT06535126
- Testing
- CanProFem-AK
- Where
- Kazakhstan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Industrial Microbiology LLP
Recurrent Vulvovaginal Candidiasis
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
In this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent…
- Trial name
- NCT06190509
- Testing
- Vaccine
- Where
- 7 sites in Belgium, Poland
- Volunteers
- 251 people
- Sponsor
- LimmaTech Biologics AG
Bacterial Vaginosis, Candidiasis
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
This research study is about vaginal infections such as bacterial vaginosis, yeast infections, and trichomoniasis. Usually, these infections can be treated with medication, but sometimes they come back after treatment.
- Conditions
- Bacterial Vaginosis, Candidiasis, Trichomoniasis
- Trial name
- NCT01230814
- Testing
- Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
- Where
- 4 sites in United States, Kenya
- Volunteers
- 234 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vaginal Candidiasis
Postbiotic as Adjunct Treatment for Vaginal Candidiasis
This project aims to study the efficacy of oral administration of postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks compared to placebo.
- Trial name
- NCT06474247
- Testing
- Postbiotic
- Where
- 2 sites in India, Malaysia
- Volunteers
- 99 people
- Sponsor
- Min-Tze LIONG
Vulvovaginal Candidiasis, Candida Infection
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply…
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT06954493
- Testing
- Ibrexafungerp
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Trichomonal Vaginitis, Bacterial Vaginosis
Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule
Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized…
- Conditions
- Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis, Mixed Vaginal Infections
- Trial name
- One-Shot (NCT06056947)
- Testing
- EVEGYN A, EVEGYN B, Gynomax® XL Vaginal Ovule
- Where
- Turkey (Türkiye)
- Volunteers
- 577 people
- Sponsor
- Ege University
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
The aim of the study is to investigate the efficacy of Fluconazol versus L-Mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. Vaginal swabs will be analyzed after 1, 6 and 12 months.
- Trial name
- NCT05367089
- Testing
- Fluconazole, L-Mesitran
- Where
- 2 sites in Netherlands
- Volunteers
- 252 people
- Sponsor
- Maastricht University Medical Center
Vulvovaginal Candidiasis, Genital
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg…
- Trial name
- NCT06411314
- Testing
- Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories
- Where
- Russia
- Volunteers
- 218 people
- Sponsor
- Avva Rus, JSC
Vulvovaginal Candidiasis
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).
- Trial name
- PROVELIA (NCT06480604)
- Testing
- Probiotic
- Where
- 6 sites in India
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Vulvovaginal Candidiasis
Comparative Performance of a Vaginal Yeast Test
The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method).
- Trial name
- NCT05079711
- Testing
- SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
- Where
- 3 sites in United States, Germany
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Uniformed Services University of the Health Sciences
Candidiasis, Vulvovaginal
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
The primary objective of this study is to study the vaginal flora colonisation equivalence between the tablet and capsule dosage forms of a treatment with Lcr Regenerans® between D0 (V1) and Dend of treatment.
- Trial name
- COMPRIGEL (NCT02730494)
- Testing
- Lcr Regenerans® vaginal capsules, Lcr Regenerans® vaginal tablet
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Biose